Prilosec delayed-release capsules and its generics had a market value of $104.5 million for the 12-month period ended January 2021, according to IQVIA.
The product is being recalled due to a market complaint received, stating that one bottle labeled as 30-count telmisartan tablets 20 mg incorrectly contained 30 tablets of 40-mg telmisartan tablets.